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Streptococcus iniae is an emerging zoonotic pathogen; 
such infections generally occur through injuries associated 
with preparing whole fresh ﬁ  sh for cooking. Those infected 
to date have been of Asian descent, are usually elderly (av-
erage age 68 years), and have had >1 underlying condi-
tions that may predispose them to infection. Studies of the 
foundations of growth characteristics of S. iniae and its in-
teractions with piscine host cells have recently been com-
plemented by molecular studies. Advances in molecular 
biology have allowed research groups to identify numerous 
virulence factors and to explore their roles in the progres-
sion of S. iniae infection. Many of these virulence factors are 
homologous to those found in the major human pathogen S. 
pyogenes. An increased understanding of the properties of 
these factors and their effect on the success of infection is 
leading to novel approaches to control S. iniae infection; in 
particular, vaccination programs at ﬁ  sh farms have reduced 
the reservoir of infection for additional clinical cases.
S
treptococcus iniae is a major ﬁ  sh pathogen in many 
regions of the world. These bacteria are also zoonotic 
with infections in humans associated with the handling 
and preparation of infected ﬁ  sh. The ﬁ  rst human infections 
were reported in 1996 (1), and S. iniae was noted as an 
emerging zoonotic disease transmitted by food animals at 
the International Conference on Emerging Infectious Dis-
eases in 2000 (2). Human infections with S. iniae have been 
sporadic but continue to be reported with new cases arising 
in 2009 (3). Reports of these cases are likely to increase be-
cause of enhanced awareness, more reliable detection and 
identiﬁ  cation methods, and the global expansion of ﬁ  nﬁ  sh 
aquaculture. Most cases of human S. iniae infections have 
been in persons of Asian descent, who are elderly and com-
monly have >1 underlying conditions such as diabetes mel-
litus, chronic rheumatic heart disease, cirrhosis, or other 
conditions (1,3–7).
Carrier ﬁ  sh have been implicated in ﬁ  sh-to-ﬁ  sh trans-
mission of S. iniae (8), and these carriers may be responsi-
ble for human infection because ﬁ  sh with overt signs of dis-
ease are unmarketable. Soft tissue injuries that occur during 
the preparation of fresh ﬁ  sh from wet markets usually result 
in bacteremic cellulitis of the hand, followed by >1 of these 
conditions: endocarditis, meningitis, arthritis, sepsis, pneu-
monia, osteomyelitis, and toxic shock (7). Infections are 
treated with a course of antimicrobial drugs such as peni-
cillin, ampicillin, amoxicillin, cloxacillin, cefazolin, and/or 
gentamicin, doxycycline, and trimethoprim/sulfamethox-
azole over a period of 1 to several weeks, depending on the 
nature of the infection (3–5,9). S. iniae is not currently as-
signed to any Lanceﬁ  eld group and is β-hemolytic on blood 
agar, with some clinical strains isolated from Asia being 
more mucoid than others (6).
Underreporting of human cases is likely because iden-
tiﬁ  cation of S. iniae is based on biochemical testing of iso-
lates with commercial kits; the use of kits is associated with 
problems because S. iniae is not listed in commercial or 
clinical databases, and many atypical strains are assigned 
low matches (1,4). According to the Australian Institute of 
Health and Welfare (www.aihw.gov.au), between 1999–
2000 and 2006–2007, a total of 2,824 cases of “other” or 
“unspeciﬁ  ed” streptococcal sepsis required hospitalization 
in Australia that were attributed to nongroup A, B, or C 
streptococci, or S. pneumoniae, and 2,026 cases were in 
persons >50 years of age. During the same period, the trend 
in the number of cases per year attributable to other or un-
speciﬁ  ed streptococci has been upward, rising from a total 
of 278 cases in 1999–2000 to 430 in 2006–2007 (155% 
increase). In the >50 years age group, this upward trend is 
more pronounced, with a 168% increase in cases requiring 
hospitalization. It is therefore probable that some cases of 
S. iniae infection in Australia in the at-risk age group have 
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been misidentiﬁ  ed. Misidentiﬁ  cation of S. iniae infection 
is likely to be the main reason for low levels of detection 
because most cases of this emerging pathogen are detected 
during retrospective studies speciﬁ  cally targeting S. iniae. 
This ﬁ  nding is likely to be the case in countries around the 
world that have reported outbreaks in ﬁ  sh farms, but no 
human cases to date. Molecular-based detection and iden-
tiﬁ  cation methods have recently been developed (informa-
tion on this aspect of identiﬁ  cation can be found in a recent 
review by Agnew and Barnes) and these will lead to im-
proved reporting in future years (10).
Observations on the epidemiology and pathogenesis 
of S. iniae infections are still ongoing; however, valuable 
information on the differentiation of strains (as being ei-
ther commensal or pathogenic) has beneﬁ  tted  research. 
Because of the lack of potential virulence factors or phe-
notypic differences between commensal and pathogenic 
strains, pulsed-ﬁ   eld gel electrophoresis (PFGE) analysis 
showed that differences existed between human clinical 
isolates and those from ﬁ  sh surfaces (1). The human clinical 
isolates showed little variation between one another, while 
considerable differences were found between the 2 Ameri-
can Type Culture Collection (Manassas, VA, USA) dolphin 
strains and 32 other ﬁ  sh isolates. It was determined that 
some unknown factors important to pathogenicity were not 
present in all strains (1). Little variation has also been found 
between clinical strains from the United States and Canada, 
although 1 strain from Pennsylvania had a PFGE pattern 
similar to the type strain (11), and 2 clinical isolates from 
Hong Kong were unrelated to a strain from Canada (4). In a 
PFGE study of isolates from Australia, similarities between 
ﬁ  sh pathogenic isolates and human clinical isolates from 
North America, in addition to multiple genotypes between 
and within different ﬁ  sh farms, were reported (12). Another 
PFGE study of strains from a variety of species of diseased 
ﬁ  sh in the People’s Republic of China found that there were 
17 genotypes from 27 strains clustering into 5 major groups 
(13). As with the study from Australia, multiple genotypes 
were found between and within different farms.
Clinical isolates from the United States were able to 
multiply by 2 to 5 generations in 3 hours in fresh human 
blood; however, 2 isolates from Canada were able to sur-
vive, but not multiply, in human blood (11). Resistance to 
phagocytic killing in whole blood by pathogenic strains of 
S. iniae contrasted with isolates identiﬁ  ed as commensal 
strains that were susceptible (9). The pathogenic strain 9117 
(a human clinical isolate causing cellulitis) caused weight 
loss in experimentally infected mice and was highly cellu-
lytic to human brain microvessel endothelial cell (BMEC) 
monolayers and invasive of Hep-2 cells. However, adher-
ence to, and invasion of, BMEC cells by strain 9117 was 
lower than that for commensal strain 9066 (obtained in a 
swab sample from a healthy ﬁ  sh) (9). In a similar study, 
pathogenic strains were more resistant to oxidative burst 
activity in macrophages (14).
The mode of invasion of S. iniae was studied in skin 
epithelial cell monolayers of rainbow trout viewed under 
polarized light (15). S. iniae adhered to, then invaded epi-
thelial cells, but its persistence and replication inside the 
cells was short-lived. However, transcytosis from epithe-
lial cells occurred within 30 minutes of contact without 
damaging the cells or cellular junctions (15). Once the 
epithelial cell layer had been breached, dissemination 
throughout the ﬁ  sh through internalization in macrophag-
es can occur. By inducing macrophage death, this process 
is one of the most efﬁ  cient ways of transporting the infec-
tion into the brain (15,16).
Recent molecular research into factors that contribute 
to the virulence of  S. iniae has identiﬁ  ed several candi-
dates, including surface proteins, capsular polysaccharides, 
and extracellular secreted products (Figure). Moreover, the 
recent sequencing of the complete genome of S. iniae will 
accelerate the discovery of additional virulence factors and 
lead to identiﬁ  cation of targets for effective vaccines for 
farmed ﬁ  sh, thus reducing the potential for zoonotic infec-
tion. In light of the recent rapid increase in our knowledge 
of this emerging pathogen, we will present a synopsis of 
the processes involved in infection that have been eluci-
dated to date.
Virulence Factors 
SiM Protein
M proteins are one of the major virulence factors in 
group A streptococci (S. pyogenes; GAS). The high level of 
diversity of emm gene types (a hypervariable gene encod-
ing the M protein) has contributed to the success of GAS in 
causing infections in humans. The M-like protein from S. 
iniae, SiM, is also a prime candidate in virulence (17,18). 
The SiM protein is a coiled-coil protein that has a molecu-
lar mass of ≈53 kDa, although 2 other variants, one with a 
1-aa insertion between the coils and another with a much 
larger mass of ≈59 kDa, have also been described (17). An 
additional variant had a natural frameshift/premature termi-
nation of the SiMA1 type in a strain from an infected tilapia 
(18). All SiM proteins possess the classical gram-positive 
membrane anchor motif LPXTG, and although they have 
several repeat motifs in the coil regions, they are not in tan-
dem as in M proteins from other species. In common with 
M proteins from S. pyogenes, S. equi, and S. dysgalactiae, 
SiM protein is a surface protein that binds human ﬁ  brino-
gen to protect the bacterium from phagocytic activity (17). 
SiM proteins may also bind trout immunoglobulin by the 
Fc region (19). An allelic exchange study showed that SiM 
protein is a major virulence factor of S. iniae, contributes to 
adherence to ﬁ  sh epithelial cells (18), and also conﬁ  rmed 
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earlier observations that SiM contributes to macrophage 
resistance (17).
The SiM protein genes, simA and simB, are likely to 
be regulated by a multigene regulatory protein, Mgx, that is 
homologous to the Mga protein found in GAS (17). There 
are sequence elements upstream of the simA and simB genes 
that are similar to DNA binding sites described for Mga. 
The ﬁ  nding of a second mga-like element (mgx2) immedi-
ately downstream of mgx in a tilapia brain abscess isolate 
may represent part of an alternative virulence strategy (18).
C5a Peptidase
C5a peptidase hydrolyses the neutrophil chemoattrac-
tant complement factor C5a (18) and thus impairs the abil-
ity of the infected host to ﬁ  ght the infection. C5a peptidase 
is a surface protein with a LPXTN gram-positive anchor 
motif (18). In GAS, C5a peptidase is found in culture su-
pernatants; however, this observation has not been made for 
S. iniae (18). In S. iniae, C5a peptidase is a 123-kDa pro-
tein, encoded by scpI, with similar structural features and 
conserved residue positions to the GAS counterpart (18). 
C5a peptidase may have arisen in S. iniae by horizontal 
gene transfer, given its close proximity to a transposase and 
similar genetic organization found in GAS (18). Notably, 
allelic exchange has shown that this protein by itself is not 
required for virulence in ﬁ  sh and its role in pathogenesis is 
likely a minor one (18).
Interleukin-8 Protease
Interleukin-8 ( IL-8) is produced in the host in response 
to stimuli such as lipopolysaccharides, viruses, and other 
cytokines. IL-8 protease is a cell envelope protease that is 
able to degrade the chemokine IL-8 and results in increased 
neutrophil resistance and disease dissemination (20). It is 
encoded by the cepI gene, resulting in a 1,631-aa protein 
with a C-terminal LPXTG gram-positive anchor motif and 
is homologous to the cepA gene in GAS (20).
Streptolysin S
The ability of S. iniae to hemolyse erythrocytes and 
damage host cell membranes results from the activity of 
cytolysins (21). The cytolysin possessed by S. iniae is 
homologous to streptolysin S (SLS) from GAS (21) and 
affects erythrocytes, neutrophils, lymphocytes, and some 
tissue types in tissue culture (22), but does not have roles 
in phagocytic resistance nor epithelial cell adherence and 
invasion (23). Nine genes in the sag operon are involved in 
SLS formation; these share 73% homology with GAS SLS 
genes (21). The number of genes and their genetic order 
are identical in both microorganisms (21). The sagA gene 
encodes a peptide that is 73% identical to the sagA protein 
from GAS, and the sagB gene encodes a protein with 77% 
identity to the sagB protein from GAS, which is predicted 
to use ﬂ  avin mononucleotide as a cofactor (21). The sagC-F 
genes are similar to their counterpart genes in GAS, and 
the sagG-I genes encode ATP binding cassette-type (ABC) 
transport systems (21). Other sequence features, such as in-
verted repeats between the sagA and sagB genes and after 
the sagI gene, have similarities with GAS sag operon genes 
(21). All genes in the operon are required to produce SLS 
as knockout of sagB in S. iniae caused loss of hemolytic 
activity (21). Likewise, when the S. iniae sagA gene was 
transformed into a nonhemolytic allelic mutant strain of 
GAS (NZ131 sagA∆cat), the S. iniae version of the sagA 
gene restored hemolytic activity (21,23). The cytotoxic 
properties of SLS toward ﬁ  sh cells and the likely promo-
tion of cerebrovascular trauma represent a major virulence 
factor in the pathogenesis of S. iniae (23).
The sagA gene in S. iniae is regulated by a 2-compo-
nent signal transduction system called sivS/R (24). sivS/R 
regulates virulence in vivo because no deaths occurred in 
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Figure. Virulence factors of Streptococcus iniae. A diagrammatic 
representation of a cell of S. iniae showing the regulatory genes 
involved in virulence factor expression (inside cell) and the 
virulence factors on the outside of the cell. In a clockwise direction, 
SiM protein (simA) expression is likely to be regulated by mgx. SiM 
protein binds immunoglobulin (Ig) and ﬁ  brinogen. C5a peptidase and 
interleukin-8 (IL-8) protease degrade their respective chemokines 
to impair phagocyte signaling. Production of the cytolysin 
streptolysin S (sag; SLS) is regulated by the sivS/R system. SLS 
lyses lymphocytes (L), erythrocytes (E), and neutrophils (N). The 
CAMP factor gene, cﬁ  , is also regulated by sivS/R and is known 
to bind immunoglobulin by the Fc region. Capsular polysaccharide 
(cpsA; CPS) synthesis is controlled by sivS/R and is represented 
by a haze around the cell. Exopolysaccharide (EPS) is produced 
in excess and contributes to highly viscous growth. α–enolase 
degrades ﬁ  brin clots and promotes dissemination.SYNOPSIS
a mouse infection model when mice were infected with 
a deletion mutant of pathogenic strain 9117 (9117∆siv) 
compared with 75% deaths when mice were infected with 
the wild type strain (24). In the siv deletion mutant, sagA 
expression was decreased by 3-fold. sivS/R also regulates 
the expression of surface proteins, including a lipoprotein/
ABC transporter homologous to Spy1228, pyruvate kinase, 
and a hyaluronate-associated protein homologous to that 
from S. equi or an ABC transporter from S. agalactiae (24). 
However, the role for these proteins in a virulence setting is 
hitherto unknown in S. iniae.
CAMP Factor
The pore-forming toxin CAMP factor synergistically 
acts with sphingomylinase-producing Staphylococcus au-
reus to produce a distinct arrow-shaped area of complete 
lysis of erythrocytes on sheep blood agar (24). CAMP 
factor has also been shown to bind immunoglobulin by 
the Fc region and therefore contributes to virulence (24). 
S. iniae harbors a CAMP factor–like gene, cﬁ  , (24) that 
encodes a peptide of ≈27 kDa and shares 62% identity 
with cfa from GAS that is regulated by the sivS/R sys-
tem. Knockout mutants of the sivS/R system resulted in a 
reduced lytic reaction, and real-time PCR analysis of cﬁ   
gene expression showed it was expressed at only 10% of 
wild-type levels (24).
Immunoglobulin-Binding Proteins
A putative protein G-like protein, a cell wall associ-
ated protein ﬁ  rst identiﬁ  ed from group G streptococci (≈70 
kDa), from S. iniae was capable of binding trout immuno-
globulin only when grown in the presence of trout serum 
(19). Proteins of ≈35 kDa, ≈70 kDa, and >100 kDa were 
found to bind trout immunoglobulin. The size of one of the 
detected bands >100 kDa is similar in size to the tetramer 
formation of SiM proteins (17); however, experimental 
evidence is needed to conﬁ  rm this. CAMP factor is also 
known to bind immunoglobulin (24).
Capsule
One of the most effective ways for a bacterium to avoid 
phagocytosis is by the production of capsular polysaccha-
ride (CPS), and strains with CPS are more virulent than 
their unencapsulated counterparts (25–27). The presence of 
capsule is also involved in inhibiting complement C3 de-
position (27). Miller and Neely (27) used signature tagged 
mutagenesis to identify virulence genes using a zebraﬁ  sh 
(Danio rerio) model. Five attenuated mutants with unique 
insertions in polysaccharide synthesis genes with homol-
ogy to those found in S. thermophilus plus 2 additional 
clones with insertions in a homologous gene near capsule 
synthesis genes from Bacteroides thetaiotaomicron were 
found. In contrast to the wild-type strain 9117, these mu-
tants aggregated in broth culture with chain lengths up to 
4× longer than the wild type. Differences in buoyancy due 
to degree of encapsulation showed that the production of 
excess capsule is likely to be as detrimental to survival as 
too little capsule (27).
The capsule operon of S. iniae is ≈21 kb in size and 
consists of 21 open reading frames (28). The genes have 
homology to genes found in other streptococci such as S. 
pyogenes, S. agalactiae, S. suis, and S. thermophilus (28). 
An insertion sequence, IS981, was found between cpsL 
and cpsM in strain 9117 (28). cpsY (78% identity to CpsY 
in GAS) precedes cpsA and is transcribed in the opposite 
direction and is thought to be the promoter of the capsule 
operon (as well as other virulence genes) because it has a 
high level of homology to the LysR transcriptional regu-
lators (28). A major difference was found in the operons 
from the virulent strain 9117 and commensal strain 9066 
with strain 9066 having an ≈10-kb deletion missing the 
genes cpsF-L and orf276, orf193, and orf151. In addition, 
the cpsM gene in the commensal strain 9066 was truncated 
with the ﬁ  rst 154 nt being absent, which casts doubt on the 
functionality of the gene (28).
The genes cpsA-E are responsible for the length of 
the monosaccharide sugar chains and their export (29,30). 
The central region of the operon from cpsF to cpsL con-
tains several genes encoding glycosyl transferases, which 
have a role in the polymerization of the capsule chain (28). 
This region is where most mutations in the virulent strain 
9117 were found to play a role in pathogenesis (27) and 
is the same region where the deleted genes in the com-
mensal strain 9066 occurred (28). The G + C content of 
the operon genes varies widely from 22% to 40% (28). 
The cpsF-L region has a G + C content of ≈27%, which 
is lower than that found for other S. iniae sequences and 
may indicate horizontal acquisition from other members 
of the Firmicutes (28).
Mutations in cpsA in strain 9117 resulted in long chain 
formation, aggregation of cells in broth culture and high 
buoyancy characteristic of reduced encapsulation (28). The 
cpsA mutant was attenuated in both brain and heart tissues. 
A cpsY mutant was slightly less encapsulated than the wild 
type and was attenuated only in heart tissue (28).
Allelic exchange of the cpsD gene resulted in reduced 
capsule, increased chain length, a marked decrease in all 
capsular monosaccharides, and a high degree of attenua-
tion (31). cpsD encodes an autophosphorylating tyrosine 
kinase thought to be responsible for capsule polymerization 
and export (31). cpsD mutants were able to bind more ef-
fectively to host tissues, such as epithelial cells, due to loss 
of overall negative charge (31). Insertions in the cpsH and 
cpsM genes have resulted in underproduction of capsule and 
overproduction of capsule, respectively (28). In a ﬂ  ounder 
isolate obtained in Japan, insertions in cpsH, cpsM, cpsI, 
1894  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009Control of S. iniae 
and orf276 of strain NUF631 resulted in attenuation, which 
was measured by increased chemiluminescence response 
of macrophages and loss of acidic polysaccharides (26). 
Like CAMP factor and streptolysin S, the 2-component 
system sivS/R is involved in transcriptional regulation of 
the capsular operon (32).
Phosphoglucomutase
Also involved in capsular biosynthesis is phosphoglu-
comutase, a 571-aa protein encoded by pgmA that intercon-
verts glucose 6-phosphate and glucose 1-phosphate (33). 
Transposon mutagenesis of the promoter region upstream 
of pgmA resulted in a highly attenuated mutant that was 
more susceptible to whole blood killing (33). This suscepti-
bility was attributed to a decrease in the amount of exopoly-
saccharide capsule on the cell surface, decreased negative 
charge, and a larger cell volume 3–5× that of the wild type. 
Increased susceptibility to the pore-forming cationic antimi-
crobial peptide moronecidin was also reported, most likely 
due to changes in cell wall architecture because of  increased 
cellular volume and a decrease in cell wall rigidity (33).
Exopolysaccharide
The quantitative composition of monosaccharides 
present in exopolysaccharide (EPS) is distinct from those 
found in CPS (34). The routine vaccination of ﬁ  sh in Israel 
has given rise to new strains of S. iniae responsible for mass 
ﬁ  sh deaths (34). These new strains were formed when an 
autogenous vaccine strain, KFP404, was succeeded by new 
strains KFP468, KFP477, and KFP523, which were char-
acterized by a viscous broth culture similar to that observed 
with S. thermophilus used in yoghurt production (34). EPS 
production by the successor strains was 5× higher than the 
autogenous vaccine strain. Vaccination of ﬁ  sh with the EPS 
extracts elicited a survival rate of 78%, which was similar 
to the 72% survival rate when whole cells were used. Thus, 
EPS appears to be antigenic and excessive production may 
have been selected by vaccination (34).
α-Enolase
The ability of S. iniae to cross tissues through plasmino-
gen activation is facilitated by α-enolase (35), which is also 
a known contributory factor to the virulence of GAS (36). 
The proteolytic activity of plasmin in dissolving ﬁ  brin clots 
enables pathogens to migrate faster through extracellular 
matrices (37), and α-enolase expedites invasion through the 
host tissues (38) and, ultimately, into the circulatory system. 
The α-enolase from S. iniae (≈50 kDa) is a plasmin/plasmi-
nogen binding enzyme that is 97% similar to the α-enolases 
of S. agalactiae and GAS (35). Immunoblot using antibodies 
raised against the puriﬁ  ed recombinant protein showed cell 
wall association in S. iniae; however, it does not contain the 
classical gram-positive membrane anchor.
Conclusions
S. iniae opportunistically infects elderly persons with 
serious underlying conditions. The expression of a suite of 
virulence factors, many of them similar to those found in 
GAS, is responsible for successful entry, propagation, and 
evasion of immune defenses of the host by this bacterium. 
Another virulence factor, polysaccharide deacetylase, en-
coded by the pdi gene, has been recently described (39). 
With the global rise of aquaculture and the dependence on it 
to provide food in many areas of the world, the numbers of 
cases of S. iniae infection are likely to be much higher than 
currently reported and will increase in the future with the 
expansion of the industry. Understanding the pathogenic 
processes of S. iniae is already facilitating the development 
of vaccines for use in ﬁ  sh farms and represents the most 
sustainable and effective method of reducing the incidence 
of economically devastating outbreaks and clinical presen-
tations in humans, especially in those most at risk.
Dr Baiano is a research ofﬁ  cer in the Centre for Marine Stud-
ies at The University of Queensland. He is a microbial ecologist 
and has research interests in marine microbiology, aquatic animal 
health, and aquaculture.
Dr Barnes is associate professor in aquatic animal health at 
The University of Queensland, Centre for Marine Studies and 
School of Biological Sciences. His research interests include ma-
rine microbiology, comparative immunology, and host–pathogen 
interactions in marine animals.
References
  1.   Weinstein MR, Litt M, Kertesz DA, Wyper P, Rose D, Coulter M, et 
al. Invasive infections due to a ﬁ  sh pathogen, Streptococcus iniae. S. 
iniae study group. N Engl J Med. 1997;337:589–94. DOI: 10.1056/
NEJM199708283370902
  2.   Hansen GR, Woodall J, Brown C, Jaax N, McNamara T, Ruiz A. 
Emerging zoonotic diseases. Panel summary from the International 
Conference on Emerging Infectious Diseases Conference, Atlan-
ta, Georgia, 2000. Emerg Infect Dis. 2001;7:537. DOI: 10.3201/
eid0703.010316
  3.   Koh TH, Sng LH, Yuen SM, Thomas CK, Tan PL, Tan SH, et al. 
Streptococcal cellulitis following preparation of fresh raw seafood. 
Zoonoses Public Health. 2009;56:206–8. DOI: 10.1111/j.1863-2378
.2008.01213.x
  4.   Lau SKP, Woo PCY, Tse H, Leung K-W, Wong SSY, Yuen K-Y. Inva-
sive Streptococcus iniae infections outside North America. J Clin Mi-
crobiol. 2003;41:1004–9. DOI: 10.1128/JCM.41.3.1004-1009.2003
  5.   Koh TH, Kurup A, Chen J. Streptococcus iniae discitis in Singapore. 
Emerg Infect Dis. 2004;10:1694–5.
  6.   Lau SKP, Woo PCY, Luk W-K, Fung AMY, Hui W-T, Fong AHC, 
et al. Clinical isolates of Streptococcus iniae from Asia are more 
mucoid and beta-hemolytic than those from North America. Di-
agn Microbiol Infect Dis. 2006;54:177–81. DOI: 10.1016/j.
diagmicrobio.2005.09.012
  7.   Sun JR, Yan JC, Yeh CY, Lee SY, Lu JJ. Invasive infection with 
Streptococcus iniae in Taiwan. J Med Microbiol. 2007;56:1246–9. 
DOI: 10.1099/jmm.0.47180-0
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009  1895 SYNOPSIS
  8.   Zlotkin A, Hershko H, Eldar A. Possible transmission of Strepto-
coccus iniae from wild ﬁ  sh to cultured marine ﬁ  sh. Appl Environ 
Microbiol. 1998;64:4065–7.
  9.   Fuller JD, Bast DJ, Nizet V, Low DE, de Azavedo JC. Streptococcus 
iniae virulence is associated with a distinct genetic proﬁ  le. Infect Im-
mun. 2001;69:1994–2000. DOI: 10.1128/IAI.69.4.1994-2000.2001
10.   Agnew W, Barnes AC. Streptococcus iniae: an aquatic pathogen of 
global veterinary signiﬁ  cance and a challenging candidate for re-
liable vaccination. Vet Microbiol. 2007;122:1–15. DOI: 10.1016/j.
vetmic.2007.03.002
11.   Facklam R, Elliot J, Shewmaker L, Reingold A. Identiﬁ  cation and 
characterization of sporadic isolates of Streptococcus iniae isolat-
ed from humans. J Clin Microbiol. 2005;43:933–7. DOI: 10.1128/
JCM.43.2.933-937.2005
12.   Nawawi RA, Baiano J, Barnes AC. Genetic variability amongst Strep-
tococcus iniae isolates from Australia. J Fish Dis. 2008;31:305–9. 
DOI: 10.1111/j.1365-2761.2007.00880.x
13.   Zhou SM, Xie MQ, Zhu XQ, Ma Y, Tan ZL, Li AX. Identiﬁ  cation 
and genetic characterization of Streptococcus iniae strains isolated 
from diseased ﬁ   sh in China. J Fish Dis. 2008;31:869–75. DOI: 
10.1111/j.1365-2761.2008.00954.x
14.   Buchanan JT, Colvin KM, Vicknair MR, Patel SK, Timmer AM, 
Nizet V. Strain-associated virulence factors of Streptococcus in-
iae in hybrid-striped bass. Vet Microbiol. 2008;131:145–53. DOI: 
10.1016/j.vetmic.2008.02.027
15.   Eyngor M, Chilmonczyk S, Zlotkin A, Manuali E, Lahav D, Ghittino 
C, et al. Transcytosis of Streptococcus iniae through skin epithelial 
barriers: an in vitro study. FEMS Microbiol Lett. 2007;277:238–48. 
DOI: 10.1111/j.1574-6968.2007.00973.x
16.   Zlotkin A, Chilmonczyk S, Eyngor M, Hurvitz A, Ghittino C, El-
dar A. Trojan horse effect: phagocyte-mediated Streptococcus iniae 
infection of ﬁ  sh. Infect Immun. 2003;71:2318–25. DOI: 10.1128/
IAI.71.5.2318-2325.2003
17.    Baiano JCF, Tumbol RA, Umapathy A, Barnes AC. Identiﬁ  ca-
tion and molecular characterisation of a ﬁ  brinogen binding pro-
tein from Streptococcus iniae. BMC Microbiol. 2008;8:67. DOI: 
10.1186/1471-2180-8-67
18.   Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT. Strep-
tococcus iniae M-like protein contributes to virulence in ﬁ  sh and 
is a target for live attenuated vaccine development. PLoS One. 
2008;3:e2824. DOI: 10.1371/journal.pone.0002824
19.   Barnes AC, Horne MT, Ellis AE. Streptococcus iniae expresses a 
cell surface non-immune trout immunoglobulin-binding factor when 
grown in normal trout serum. Fish Shellﬁ  sh Immunol. 2003;15:425–
31. DOI: 10.1016/S1050-4648(03)00021-4
20.    Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan 
JT, Turner CE, et al. The IL-8 protease SpyCEP/ScpC of group A 
streptococcus promotes resistance to neutrophil killing. Cell Host 
Microbe. 2008;4:170–8. DOI: 10.1016/j.chom.2008.07.002
21.   Fuller JD, Camus AC, Duncan CL, Nizet V, Bast DJ, Thune RL, et 
al. Identiﬁ  cation of a streptolysin S–associated gene cluster and its 
role in the pathogenesis of Streptococcus iniae disease. Infect Im-
mun. 2002;70:5730–9. DOI: 10.1128/IAI.70.10.5730-5739.2002
22.   Nizet V, Beall B, Bast DJ, Datta V, Kilburn L, Low DE, et al. Genetic 
locus for streptolysin S production by group A Streptococcus. Infect 
Immun. 2000;68:4245–54. DOI: 10.1128/IAI.68.7.4245-4254.2000
23.   Locke JB, Colvin KM, Varki N, Vicknair MR, Nizet V, Buchanan JT. 
Streptococcus iniae β-hemolysin streptolysin S is a virulence factor 
in ﬁ  sh infection. Dis Aquat Organ. 2007;76:17–26. DOI: 10.3354/
dao076017
24.   Bolotin S, Fuller JD, Bast DJ, de Azavedo JCS. The two-component 
system sivS/R regulates virulence in Streptococcus iniae. FEMS Im-
munol Med Microbiol. 2007;51:547–54. DOI: 10.1111/j.1574-695-
X.2007.00334.x
25.   Kanai K, Notohara M, Kato T, Shutou K, Yoshikoshi K. Serologi-
cal characterization of Streptococcus iniae strains isolated from cul-
tured ﬁ  sh in Japan. Fish Pathology. 2006;41:57–66. DOI: 10.3147/
jsfp.41.57
26.   Shutou K, Kanai K, Yoshikoshi K. Virulence attenuation of capsular 
polysaccharide-deleted mutants of Streptococcus iniae in Japanese 
ﬂ  ounder Paralicthys olivaceus. Fish Pathology. 2007;42:42–8.
27.   Miller JD, Neely MN. Large-scale screen highlights the importance 
of capsule for virulence in the zoonotic pathogen Streptococcus 
iniae. Infect Immun. 2005;73:921–34. DOI: 10.1128/IAI.73.2.921-
934.2005
28.   Lowe BA, Miller JD, Neely MN. Analysis of the polysaccharide 
capsule of the systemic pathogen Streptococcus iniae and its im-
plications in virulence. Infect Immun. 2007;75:1255–64. DOI: 
10.1128/IAI.01484-06
29.   Grifﬁ  n AM, Morris VJ, Gasson MJ. The cpsABCDE genes involved 
in polysaccharide production in Streptococcus salivarius ssp. ther-
mophilus strain NCBF2393. Gene. 1996;183:23–7. DOI: 10.1016/
S0378-1119(96)00405-2
30.   Morona JK, Miller DC, Morona R, Paton JC. The effect that muta-
tions in the conserved capsular regions polysaccharide biosynthesis 
genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneu-
moniae. J Infect Dis. 2004;189:1905–13. DOI: 10.1086/383352
31.   Locke JB, Colvin KM, Datta AK, Patel SK, Naidu NN, Neely MN, 
et al. Streptococcus iniae capsule impairs phagocytic clearance and 
contributes to virulence in ﬁ  sh. J Bacteriol. 2007;189:1279–87. DOI: 
10.1128/JB.01175-06
32.   Bolotin S, Fuller JD, Bast DJ, Beveridge TJ, de Azavedo JCS. Cap-
sule expression regulated by a two-component signal transduction 
system in Streptococcus iniae. FEMS Immunol Med Microbiol. 
2007;50:366–74. DOI: 10.1111/j.1574-695X.2007.00261.x
33.   Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, West-
erman ME, et al. Streptococcus iniae phosphoglucomutase is a viru-
lence factor and a target for vaccine development. Infect Immun. 
2005;73:6935–44. DOI: 10.1128/IAI.73.10.6935-6944.2005
34.   Eyngor M, Tekoah Y, Shapira R, Hurvitz A, Zlotkin A, Lublin A, et 
al. Emergence of novel Streptococcus iniae exopolysaccharide-pro-
ducing strains following vaccination with nonproducing strains. Appl 
Environ Microbiol. 2008;74:6892–7. DOI: 10.1128/AEM.00853-08
35.   Kim MS, Choi SH, Lee EH, Nam YK, Kim SK, Kim KH. α-enolase, 
a plasmin(ogen) binding protein and cell wall associating protein 
from a ﬁ  sh  pathogenic  Streptococcus iniae strain. Aquaculture. 
2007;265:55–60. DOI: 10.1016/j.aquaculture.2007.01.034
36.   Pancholi V, Fischetti VA. Alpha-enolase, a novel strong plasmin
(ogen) binding protein on the surface of pathogenic streptococci. J 
Biol Chem. 1998;273:14503–15. DOI: 10.1074/jbc.273.23.14503
37.    Eberhard T, Kronvall G, Ullberg MBB. Surface bound plasmin 
promotes migration of Streptococcus pneumoniae through reconsti-
tuted basement membranes. Microb Pathog. 1999;26:175–81. DOI: 
10.1006/mpat.1998.0262
38.   Lottenberg R. A novel approach to explore the role of plasminogen 
in bacterial pathogenesis. Trends Microbiol. 1997;5:466–7. DOI: 
10.1016/S0966-842X(97)01171-2
39.   Milani CJ, Aziz RK, Locke JB, Dahesh S, Nizet V, Buchanan JT. 
The novel polysaccharide deacetylase homolog Pdi contributes to 
virulence of the aquatic pathogen Streptococcus iniae. Microbiol-
ogy. 2009. In press. DOI: 10.1099/mic.0.028365-0 
Address for correspondence: Justice C.F. Baiano, The University of 
Queensland, Aquatic Animal Health Laboratory, Centre for Marine 
Studies, St. Lucia, Queensland 4072, Australia; email: justice.baiano@
gmail.com 
1896  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009